{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:57:04Z","timestamp":1792792624493,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.leukres.2024.107564","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:53:51Z","timestamp":1724349231000},"page":"107564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed\/refractory FLT3 acute myeloid leukemia"],"prefix":"10.1016","volume":"145","author":[{"given":"Qiang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107564_bib1","first-page":"124","article-title":"Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study","volume":"10","author":"Brandwein","year":"2020","journal-title":"Am. J. Blood Res"},{"key":"10.1016\/j.leukres.2024.107564_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"DeWolf","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107564_bib3","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107564_bib4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2024.107564_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107564_bib6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107564_bib7","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2024.107564_bib8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107564_bib9","first-page":"6766","article-title":"Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics","author":"Tao","year":"2019","journal-title":"Oncol. Lett. 18"},{"key":"10.1016\/j.leukres.2024.107564_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2024.107564_bib11","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107564_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107564_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s44178-024-00078-9","article-title":"CACA guidelines for holistic integrative management of adult acute myeloid leukemia","volume":"3","author":"Wei","year":"2024","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.leukres.2024.107564_bib14","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107564_bib15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107564_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2023","journal-title":"J. Intern Med"},{"key":"10.1016\/j.leukres.2024.107564_bib17","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1038\/s41467-019-10345-3","article-title":"Curvature induction and membrane remodeling by FAM134B reticulon homology domain assist selective ER-phagy","volume":"10","author":"Bhaskara","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2024.107564_bib18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107564_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25929","article-title":"Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia","author":"Aldoss","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107564_bib20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107564_bib21","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107564_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2024.107564_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107564_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","article-title":"Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia","volume":"11","author":"Maiti","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107564_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \"triplet\" therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107564_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.26447","article-title":"Gilteritinib clinical activity in relapsed\/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors","volume":"97","author":"Numan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107564_bib27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107564_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V97.1.89","article-title":"Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia","volume":"97","author":"Meshinchi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107564_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/hon.3186","article-title":"The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation","volume":"41","author":"Tang","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107564_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-008-0591-8","article-title":"Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia","volume":"88","author":"Ruan","year":"2009","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2024.107564_bib31","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00277-013-1733-1","article-title":"Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity","volume":"92","author":"Zhao","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2024.107564_bib32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107564_bib33","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107564_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41375-022-01742-7","article-title":"Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO","volume":"37","author":"Dumas","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107564_bib35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","article-title":"Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107564_bib36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11427-019-9594-7","article-title":"Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF\/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)","volume":"63","author":"Tang","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.leukres.2024.107564_bib37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11427-018-9509-y","article-title":"Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation","volume":"63","author":"Tang","year":"2020","journal-title":"Sci. China Life Sci."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T12:52:53Z","timestamp":1726231973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"alternative-id":["S0145212624001309"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107564","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed\/refractory FLT3mut acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107564"}}